Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.91 CAD | +4.23% | -3.11% | -5.29% |
04-16 | KITS Eyecare Ltd. Announces Executive Appointments | CI |
04-10 | Kits Eyecare Announces Sabrina Liak Will Transition to Senior Advisor Role and Continue as Board Member | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by -99% by 2026.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Other Specialty Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.29% | 136M | - | ||
-14.57% | 1.4B | C | ||
+15.07% | 713M | - | ||
-30.64% | 483M | - | ||
-23.65% | 364M | - | ||
+21.86% | 188M | - | - | |
-23.15% | 128M | - | - | |
-4.91% | 109M | - | ||
+0.33% | 92.65M | - | - | |
+2.82% | 70.73M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- KITS Stock
- Ratings Kits Eyecare Ltd.